Post by Halozyme, Inc.

At Controlled Release Society (CRS) 2026 Annual Meeting this week? Go say hello to Halozyme’s David Kang, Director, Drug Delivery, and Chris Wahl, Chief Scientific Officer, who are sharing posters on "Ultrahigh‑Concentration Subcutaneous Delivery of Biotherapeutics Enabled by a High Glass Transition Temperature Excipient" and "Enhanced SC Delivery of ADCs with rHuPH20: PK and Tolerability in Minipigs".